Healthcare Services Group (HCSG) reported third-quarter earnings of $0.36 per share, beating the $0.22 consensus by 63.6%. On Earnings Whispers' normalized basis, earnings grew 56.5% year over year. Revenue of $479.6 million rose 3.3% and was essentially in line with the $479.93 million consensus, a 0.1% shortfall. The most important development was not the beat. It was management's decision to reset the growth narrative: the company closed the NEXDINE Hospitality acquisition, guided fourth-quarter revenue to $535-$545 million, and raised its 2027 revenue growth outlook from mid single digits to low double digits. A company that has been grinding out low-single-digit growth is now asking investors to underwrite an acceleration.
The quality of the beat deserves scrutiny. Cost of services ran at 83.2% of revenue, well below the company's 86% management goal. That figure included a $6.1 million estimated Genesis bankruptcy recovery, which the call indicated was split roughly evenly between the two segments. At the quarter's 26.2% tax rate, that recovery is worth roughly six to seven cents per share on our rough estimate, a meaningful slice of the margin over consensus. A lower diluted share count also helped: it was 69.4 million versus 73.0 million a year ago, after $56.6 million of buybacks year to date. Investors should note one conflict. GAAP diluted EPS actually fell from $0.59 in the year-ago quarter, but that period was inflated by $11.4 million of other income and a cost-of-services ratio near 79%. Adjusted EBITDA margin was 8.0%, against 12.1% a year earlier.
Cash flow is the weakest part of the print. Operating cash flow excluding the payroll accrual was $20.7 million, down from $87.1 million a year ago. Accounts receivable climbed to $309.6 million from $281.3 million at year-end. Long-term notes receivable rose to $42.4 million from $25.2 million, a reminder that customer credit remains a live issue in this business. Management also flagged that payroll-accrual timing will reduce reported fourth-quarter operating cash flow by about $18 million, with a reversal expected in the first quarter of 2027.
The call preserved a credible growth story, and the numbers behind it are concrete. Revenue moved from $462.8 million in Q1 to $470.8 million in Q2 to $479.6 million in Q3, sequential gains of roughly $8-9 million. The fourth-quarter guide implies a step-up of about $60 million. NEXDINE, expected to contribute more than $150 million in annual revenue, accounts for only part of that increase. The remainder is organic, which marks a genuine acceleration versus earlier back-half ramp language. One transcription of the call showed a $435-$445 million range, but the release and the analyst's sequential math both point to $535-$545 million. Management described NEXDINE as a double-digit grower with comparable margins, full cost pass-through contracts, and immediate accretion even after lost interest income. It also framed the deal as a cross-selling platform alongside Campus Services Group and Meriwether Godsey, and signaled an active M&A posture.
Bears have legitimate ammunition on the cost side. SG&A rose on legal, professional and deal fees to an adjusted 10.2% of revenue. That remains within the 9.5%-10.5% target range, but management gave no timeline for reaching the 8.5%-9.5% longer-term goal. Net interest income already fell to $2.2 million from $7.5 million, and deploying $93.5 million of cash will reduce it further. NEXDINE's intangible amortization and earn-out liability have not been quantified. Management also declined to lower its 86% cost-of-services target despite repeated outperformance, citing lumpy bad debt and workers' compensation. Workers' comp benefits already fell from more than $4.5 million in Q1 to $1.3 million in Q2. On the positive side, the final Genesis resolution carries a "substantially higher" potential upper-range recovery, though its timing and amount are unknown.
The market setup is more complicated than the surprise implies. Investor sentiment remained positive but weakened ahead of the report, sliding from 0.48 to 0.34. Shares closed at $21.50 on October 20, down 10.5% from the $24.02 opening after the July report. They have retreated 13.6% from the $24.90 inter-earnings high set that same day, after touching a $20.17 low on October 1. The stock entered the report just 1.5% above its 200-day moving average, holding a key trend level rather than trading with conviction. The trend readings are mixed, with sequential growth positive while AVWAP remains negative.
The bottom line is that HCSG delivered a large headline beat with help from a Genesis recovery and favorable cost items, and its cash flow and margin comparisons were softer than the EPS figure suggests. What changed the investment setup is the growth outlook: a sharply higher fourth-quarter revenue guide, a raised 2027 target, and an acquisition that expands the company's reach into senior living and hospitality. Execution on integration, SG&A discipline, and credit quality will determine whether the market rewards that reset after a quarter of fading sentiment and price.